Presentation and Questions werent very fruitful, didnt think presentation would give much more than the webinar. Questions very repetitive.
Anyways, will wait for further data to be unpacked.
Biggest take aways:
- institutions interested in investigating ATH434 effects in PD.
- Ongoing frequent discussions with FDA and EPA to get what is needed to get AA.
- There are getting more biomarker information.
- UMSARS was the most important clinical endpoint to support regulatory approval for MSA treatment.
- Data package to be ready by next scientific presentation as there is a tremendous amount of interest.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
-0.001(5.00%) |
Mkt cap ! $86.71M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $10.38K | 1.132M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 10530778 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 7264518 | 8 |
View Market Depth
| Last trade - 13.42pm 26/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |